- Home
- CRIS vs SABS Comparison
CRIS vs SABS Comparison
Compare CRIS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- SABS
- Stock Information
- Founded
- CRIS 2000
- SABS 2014
- Country
- CRIS United States
- SABS United States
- Employees
- CRIS N/A
- SABS N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- SABS Health Care
- Exchange
- CRIS Nasdaq
- SABS Nasdaq
- Market Cap
- CRIS 32.8M
- SABS 32.1M
- IPO Year
- CRIS 2000
- SABS N/A
- Fundamental
- Price
- CRIS $3.29
- SABS $3.53
- Analyst Decision
- CRIS Strong Buy
- SABS Strong Buy
- Analyst Count
- CRIS 3
- SABS 5
- Target Price
- CRIS $23.00
- SABS $12.40
- AVG Volume (30 Days)
- CRIS 243.3K
- SABS 69.6K
- Earning Date
- CRIS 02-06-2025
- SABS 11-06-2024
- Dividend Yield
- CRIS N/A
- SABS N/A
- EPS Growth
- CRIS N/A
- SABS N/A
- EPS
- CRIS N/A
- SABS N/A
- Revenue
- CRIS $10,259,000.00
- SABS $1,512,723.00
- Revenue This Year
- CRIS N/A
- SABS N/A
- Revenue Next Year
- CRIS N/A
- SABS N/A
- P/E Ratio
- CRIS N/A
- SABS N/A
- Revenue Growth
- CRIS 0.44
- SABS N/A
- 52 Week Low
- CRIS $2.86
- SABS $2.16
- 52 Week High
- CRIS $17.49
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- CRIS 44.97
- SABS 46.39
- Support Level
- CRIS $3.10
- SABS $3.50
- Resistance Level
- CRIS $3.60
- SABS $4.35
- Average True Range (ATR)
- CRIS 0.37
- SABS 0.41
- MACD
- CRIS 0.00
- SABS -0.07
- Stochastic Oscillator
- CRIS 26.22
- SABS 19.22
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.